Search results
Results from the WOW.Com Content Network
Donepezil, sold under the brand name Aricept among others, is a medication used to treat dementia of the Alzheimer's type. [5] [6] [10] It appears to result in a small benefit in mental function and ability to function. [11] Use, however, has not been shown to change the progression of the disease. [12] Treatment should be stopped if no benefit ...
Galantamine, sold under the brand name Razadyne among others, is indicated for the treatment of mild to moderate vascular dementia and Alzheimer's disease. [6] [7] The first person to extract galantamine and theorize its usefulness in medicine, was the Bulgarian chemist Dimitar Paskov in 1959.
Vascular dementia is dementia caused by a series of strokes. [ 2 ] [ 4 ] Restricted blood flow due to strokes reduces oxygen and glucose delivery to the brain, causing cell injury and neurological deficits in the affected region. [ 6 ]
Not only that, they had a 52 percent lower risk of vascular dementia, and a 39 percent lower risk of Alzheimer’s dementia. People who took SGLT-2 inhibitors for longer periods of time seemed to ...
Memantine when added to donepezil in those with moderate-to-severe dementia resulted in "limited improvements" in a 2017 review. [24] The UK National Institute for Clinical Excellence (NICE) issued guidance in 2018 recommending consideration of the combination of memantine with donepezil in those with moderate-to-severe dementia.
Rivastigmine, sold under the brand name Exelon among others, is an acetylcholinesterase inhibitor used for the treatment of dementia associated with Alzheimer's disease and with Parkinson's disease. [ 4 ] [ 6 ] [ 7 ] Rivastigmine can be administered orally or via a transdermal patch ; the latter form reduces the prevalence of side effects, [ 8 ...
MeSH F03.550.150 – attention deficit and disruptive behavior disorders; MeSH F03.550.150.150 – attention deficit disorder with hyperactivity; MeSH F03.550.150.300 – conduct disorder; MeSH F03.550.300 – child behavior disorders; MeSH F03.550.325 – child development disorders, pervasive; MeSH F03.550.325.100 – asperger syndrome
Early onset dementia is less common than late onset dementia, the former accounting for approximately 10% of dementias globally. [3] Recent studies estimate the prevalence of early onset dementia to be approximately 3.55 million people aged 30–64 worldwide, and will triple by 2050. [7] with an incidence of 119 per 100,000 individuals. [1]